AGL 37.94 No Change ▼ 0.00 (0%)
AIRLINK 161.70 Increased By ▲ 6.48 (4.17%)
BOP 8.96 Decreased By ▼ -0.11 (-1.21%)
CNERGY 6.85 Increased By ▲ 0.13 (1.93%)
DCL 10.05 Increased By ▲ 0.52 (5.46%)
DFML 40.40 Increased By ▲ 0.09 (0.22%)
DGKC 91.66 Decreased By ▼ -1.29 (-1.39%)
FCCL 38.09 Decreased By ▼ -0.29 (-0.76%)
FFBL 78.45 Decreased By ▼ -0.13 (-0.17%)
FFL 13.47 Decreased By ▼ -0.13 (-0.96%)
HUBC 113.50 Increased By ▲ 3.31 (3%)
HUMNL 14.56 Decreased By ▼ -0.33 (-2.22%)
KEL 5.64 Decreased By ▼ -0.09 (-1.57%)
KOSM 8.19 Decreased By ▼ -0.28 (-3.31%)
MLCF 44.85 Decreased By ▼ -0.81 (-1.77%)
NBP 74.98 Decreased By ▼ -1.19 (-1.56%)
OGDC 192.20 Increased By ▲ 0.33 (0.17%)
PAEL 31.90 Increased By ▲ 1.42 (4.66%)
PIBTL 8.38 Increased By ▲ 0.22 (2.7%)
PPL 166.99 Increased By ▲ 0.43 (0.26%)
PRL 31.43 Increased By ▲ 1.99 (6.76%)
PTC 22.08 Increased By ▲ 2.01 (10.01%)
SEARL 97.69 Increased By ▲ 1.07 (1.11%)
TELE 8.50 Increased By ▲ 0.23 (2.78%)
TOMCL 34.40 Increased By ▲ 0.14 (0.41%)
TPLP 11.10 Increased By ▲ 0.88 (8.61%)
TREET 18.02 Increased By ▲ 0.36 (2.04%)
TRG 61.27 Increased By ▲ 0.02 (0.03%)
UNITY 32.35 Increased By ▲ 0.38 (1.19%)
WTL 1.53 Increased By ▲ 0.06 (4.08%)
BR100 11,239 Increased By 23.4 (0.21%)
BR30 33,901 Increased By 250.2 (0.74%)
KSE100 104,750 Increased By 191.3 (0.18%)
KSE30 32,404 Increased By 38.5 (0.12%)
Business & Finance

CureVac teams up with Swiss contract drugmaker Celonic to boost COVID-19 vaccine output

  • Celonic plans to manufacture the mRNA molecules that make up the vaccine, with up to 50 million doses expected by the end of 2021, the companies said.
  • The vaccine candidate, CVnCoV, whose late-stage trials began in December, will be produced at Celonic's facility in Heidelberg, Germany.
Published March 30, 2021

German biotech firm CureVac NV said on Tuesday it had partnered with Swiss contract manufacturer Celonic Group to produce more than 100 million doses of its COVID-19 vaccine candidate, its latest move to boost vaccine output in Europe.

Celonic plans to manufacture the mRNA molecules that make up the vaccine, with up to 50 million doses expected by the end of 2021, the companies said.

The vaccine candidate, CVnCoV, whose late-stage trials began in December, will be produced at Celonic's facility in Heidelberg, Germany.

Earlier this month, CureVac enlisted Swiss pharmaceutical giant Novartis AG to help produce its COVID-19 vaccine. It has also partnered with Bayer AG, family-owned Fareva of France, Wacker and Rentschler Biopharma SE.

CureVac reiterated that it aims to produce up to 300 million doses of the vaccine in 2021.

Comments

Comments are closed.